BACKGROUND To reduce the number of patients with depression, biomarkers for clarifying psychiatric disorders are warranted. Numerous candidates have been proposed; however, near-infrared spectroscopy (NIRS) with multi-channel probes and a dexamethasone/corticotropin-releasing hormone (DEX/CRH) test are still surviving for practical demand. Thirty-one outpatients with depressed moods were analyzed using both biological tests. RESULTS The non-suppressors, as indicated by the DEX/CRH test, exhibited a high severity on the Hamilton Depression Scale and severe anxiety on the State Trait Anxiety Scale. In addition, a unique response was identified via NIRS in the same group suggested by the DEX/CRH assessment. CONCLUSIONS The results obtained from these biological tests did not fit well with the category defined by operative diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders or The International Classification of Diseases. Thus, it is critical that the utility evaluations of candidate biomarkers not be assessed by comparisons with the categorized criteria for a specific psychiatric disorder. Trial registration UMIN000013214, Registered 21 February 2014.

中文翻译：

---

DEX / CRH测试和多通道NIRS在抑郁症患者中的临床应用。

背景技术为了减少患有抑郁症的患者的数量，需要用于澄清精神疾病的生物标记。已经提出了许多候选人。但是，具有多通道探针和地塞米松/促肾上腺皮质激素释放激素（DEX / CRH）测试的近红外光谱（NIRS）仍然可以满足实际需求。使用这两种生物学测试对31名情绪低落的门诊患者进行了分析。结果如DEX / CRH测试所示，非抑制剂在汉密尔顿抑郁量表上表现出较高的严重性，在状态特质焦虑量表上表现出严重的焦虑。此外，在DEX / CRH评估建议的同一组中，通过NIRS识别出了独特的反应。结论从这些生物学测试中获得的结果与手术诊断标准所定义的类别不完全吻合，例如《精神疾病诊断和统计手册》或《国际疾病分类》。因此，至关重要的是，不能通过与针对特定精神病的分类标准进行比较来评估候选生物标志物的效用评估。尝试注册UMIN000013214，于2014年2月21日注册。